Peptide radiopharmaceuticals: how Lutathera and Pluvicto find cancer

What a radioligand is

Every radioligand in clinical use has the same three-part design. A targeting molecule seeks out a receptor that cancer cells carry in large amounts. A chelator, a molecular cage such as DOTA, holds a radioactive metal tightly. And the metal itself decays, giving off radiation that either shows up on a scanner or damages DNA in the cells around it ^{1 2}.

In Lutathera the targeting part is octreotate, an eight-amino-acid peptide closely related to octreotide, which binds somatostatin receptors. Neuroendocrine tumours, which arise from hormone-making cells in the gut, pancreas and lungs, often carry these receptors densely. In Pluvicto the targeting part is PSMA-617 (vipivotide tetraxetan), a small peptide-like molecule built around a glutamate-urea-lysine motif that binds prostate-specific membrane antigen, an enzyme heavily expressed on most prostate cancers. Strictly, PSMA-617 is a peptidomimetic rather than a peptide, but it is designed on the same principle.

The radioactive metal in both is lutetium-177. It emits beta particles that travel only about a millimetre or two in tissue, enough to hit the tumour cell that took up the drug and its neighbours while sparing most of the body. It also emits a little gamma radiation, which lets doctors image where the dose went.

Theranostics: see it, then treat it

The word theranostics joins therapy and diagnostics. The same targeting molecule is first labelled with a short-lived positron emitter, usually gallium-68, and used for a PET scan. If the tumours light up, they carry enough of the target for the lutetium version to reach them. If they do not, treatment is unlikely to work, and patients are spared the radiation.

For neuroendocrine tumours that scan is gallium-68 dotatate (sold as NETSPOT), labelled for locating somatostatin receptor-positive tumours in adults and children ³; a copper-64 version and gallium-68 DOTATOC do the same job. For prostate cancer it is a gallium-68 PSMA tracer such as gozetotide. Every trial below enrolled only patients whose scans showed the target, which is part of why the results are as strong as they are: the drugs were tested in the people most likely to respond.

Imaging also matters after treatment starts. Because the PET tracer and the treatment share a target, a scan can show which deposits took up the drug, and a later scan can show whether they have changed. The gamma rays lutetium-177 gives off allow imaging after each infusion too, which is how the dosimetry studies below measured where the radiation went.

Our Peptide Drug Registry lists 14 rows for radiolabelled peptides and their relatives: eight marked approved, including the imaging agents and older indium-111 tracers, and six in phase 2 by its sources, among them newer lutetium agents aimed at other targets ⁴.

Lutathera: the NETTER trials

NETTER-1 randomised 229 patients with advanced midgut neuroendocrine tumours that had progressed on standard octreotide. One group received four infusions of lutetium-177 dotatate, 7.4 GBq every eight weeks, plus standard-dose octreotide; the other received high-dose octreotide alone. At 20 months, 65.2% of the Lutathera group were alive without progression against 10.8% of the control group, and 18% against 3% saw their tumours shrink (randomised trial) ⁵.

The interim survival analysis looked promising, but the final analysis, five years after the last patient joined, did not confirm it: median overall survival was 48.0 months with Lutathera and 36.3 months with high-dose octreotide, a difference that was not statistically significant. Many control patients later received Lutathera-type treatment, which blurs the comparison. Two of 111 treated patients developed myelodysplastic syndrome, a bone-marrow disorder, one of whom died (randomised trial, long-term follow-up) ⁶.

NETTER-2 moved treatment earlier. It randomised 226 patients with newly diagnosed, faster-growing (grade 2 or 3) gastroenteropancreatic neuroendocrine tumours to Lutathera plus octreotide or high-dose octreotide as first treatment. Median progression-free survival was 22.8 months against 8.5 months, and there were no treatment-related deaths during treatment (randomised trial) ⁷.

The current US label covers somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, from foregut, midgut and hindgut, in adults and in children aged 12 and older, at 7.4 GBq (200 mCi) every eight weeks for four doses, with dose reductions to 3.7 GBq for low blood counts ¹.

Pluvicto: VISION, PSMAfore and PSMAddition

VISION was the trial that made PSMA radioligand therapy standard. It randomised 831 men with PSMA-positive metastatic castration-resistant prostate cancer, already treated with hormone-pathway drugs and chemotherapy, to Pluvicto plus standard care or standard care alone. Imaging-based progression-free survival was 8.7 against 3.4 months, and overall survival 15.3 against 11.3 months, a 38% reduction in the risk of death. Serious (grade 3 or higher) side effects were more common with Pluvicto, 52.7% against 38.0%, but quality of life was not worse (randomised trial) ⁸.

PSMAfore tested it before chemotherapy. In 468 men whose cancer had progressed on one hormone-pathway drug, Pluvicto against a switch to a different one gave a median radiographic progression-free survival of 9.3 against 5.6 months at the first analysis and 11.6 against 5.6 months later; grade 3 to 5 side effects were less common with Pluvicto. More than half the comparison group later crossed over to Pluvicto, which makes any survival difference hard to measure (randomised trial) ⁹.

PSMAddition moved it earlier still, into cancer that still responds to hormone therapy. Among 1,144 men, adding Pluvicto to standard hormone treatment cut the risk of radiographic progression or death by 28% (hazard ratio 0.72) at the second interim analysis, though median progression-free survival had not been reached in either group; serious side effects occurred in 51% against 43% (randomised trial) ¹⁰.

The August 2026 US label now covers both settings: with hormone-pathway therapy for PSMA-positive metastatic prostate cancer that is hormone-naive or hormone-sensitive, and alone for hormone-resistant disease after a hormone-pathway drug, either before chemotherapy or after it. The dose in both is 7.4 GBq (200 mCi) every six weeks for six doses, reduced once by 20% to 5.9 GBq for toxicity ².

Shrinking tumours are not the whole story

Neuroendocrine tumours often stop growing without getting much smaller, and the NETTER-1 data show why shrinkage is a poor guide to benefit. Among 117 patients given Lutathera, only 15% saw their tumours shrink by 30% or more, and best tumour shrinkage was not associated with how long patients stayed free of progression; median progression-free survival was in fact 25.0 months in those with less shrinkage against 17.6 months in those with more (secondary analysis of a randomised trial) ¹¹. For patients, a stable scan after treatment can be a good result.

A dosimetry substudy of 20 NETTER-1 patients measured where the radiation went. The kidneys absorbed a mean of 19.4 Gy over four cycles and the bone marrow about 1.0 Gy, with wide variation between people; the three patients with kidney doses of 28 to 33 Gy showed at most a mild rise in creatinine over up to five years. Tumour doses varied enormously, from 7 to 2,218 Gy, and did not predict how much a tumour shrank, although 90% shrank to some degree (dosimetry substudy) ¹². Fixed dosing, the way the labels prescribe it, delivers very different doses to different people, which is why some centres argue for measuring each patient's dose.

Do the results hold outside trials?

Trials enrol fitter patients than clinics see. When 117 men treated with Pluvicto in the US expanded-access programme, before approval, were compared with VISION, they had received more hormone-pathway drugs and more often had poor performance status, yet their median overall survival (15.1 against 15.3 months), PSA response rate (42% against 46%) and rates of serious anaemia, low platelets and low white cells were similar (comparison with a trial) ¹³.

VISION has also drawn methodological criticism. Writing in European Urology, oncologists argued that its control arm was weakened by limits on which standard treatments were allowed, by some patients first judged unable to have chemotherapy later receiving it, and by many control patients leaving the trial early. They also noted that the cost of Lu-PSMA therapy will put it out of reach in many countries (commentary) ¹⁴. The survival benefit stood, but how large it would be against the best available care is less certain than the headline numbers suggest.

What comes next

The next step being tested is a heavier particle. Alpha emitters such as actinium-225 deposit far more energy over a far shorter distance than lutetium-177's beta particles. A 2026 review of PSMA radioligand therapy describes actinium-225 PSMA compounds as possibly active in some men whose cancer has progressed after lutetium treatment, while stressing that definitive phase 3 evidence is still lacking and that salivary, blood and kidney toxicities all need managing as use expands (review) ¹⁵.

New targets are also arriving. The Registry's phase 2 rows include lutetium agents aimed at receptors other than somatostatin and PSMA, and lutetium-177 edotreotide, a close cousin of Lutathera built on the octreotide-like peptide used in gallium-68 DOTATOC scans ⁴. Our edotreotide entry follows that programme.

What a course of treatment involves

For Pluvicto, the label requires a PSMA PET scan, with Locametz or another approved PSMA imaging agent, to show that the tumours express the target before treatment is chosen ². Each dose is then given every six weeks, up to six doses, with blood counts and kidney function checked before each one. The label sets out when to hold or reduce a dose: for example, moderate dry mouth means pausing until it settles, and severe dry mouth that comes back after a dose reduction means stopping for good ².

Lutathera's routine is more involved, because it is given alongside the octreotide it is built on. Long-acting octreotide must be stopped at least four weeks before the first dose, so it does not block the receptors the drug needs. On treatment days, patients receive anti-nausea medicine and then an intravenous amino-acid solution, started 30 minutes before the Lutathera infusion, which reduces how much radiation the kidneys absorb; the amino-acid dose is not cut even when the Lutathera dose is. Long-acting octreotide is restarted 4 to 24 hours after each dose and continued every four weeks after the course, for up to 18 months from the start ¹.

A full course therefore runs about seven months for Lutathera (four doses, eight weeks apart) and up to about nine months for Pluvicto (six doses, six weeks apart). Some of the radiation leaves the body in urine, so the Pluvicto label tells patients to drink more fluids and urinate often, both to spare the bladder and to protect the kidneys, and asks treatment teams to keep radiation exposure to the patient's household and staff as low as their safety procedures allow. Because it can harm a developing baby and may cause temporary or permanent infertility, men with partners who could become pregnant are advised to use effective contraception ².

The risks

Radiation goes where the target is, and some healthy tissues carry the targets too or clear the drug. The Pluvicto label's warnings cover radiation exposure to others, bone-marrow suppression, kidney toxicity, harm to a developing baby and infertility ². Salivary and tear glands take up PSMA tracers, so dry mouth is common with Pluvicto. Low blood counts are the main dose-limiting effect of both drugs, and the NETTER-1 follow-up recorded myelodysplastic syndrome in 2% of treated patients ⁶.

Both are given as intravenous infusions by nuclear medicine teams, with amino-acid infusions alongside Lutathera to protect the kidneys, and patients are told how to limit close contact with others for a period after each dose. None of this resembles the peptides sold online: radioligands are made to order from short-lived isotopes in licensed facilities and cannot be bought or self-administered.

Questions to ask a specialist

• Did my PET scan show enough target uptake for this treatment to be worthwhile?
• Would starting earlier, as in NETTER-2 or PSMAfore, make sense for my stage of disease?
• How will my blood counts and kidney function be monitored between doses?
• What precautions will I need to take around family after each infusion, and for how long?

How it adds up (as of October 4, 2026)

Radioligand therapy pairs a targeting molecule with a radioactive metal and checks the target with a PET scan first. Lutathera, for somatostatin receptor-positive neuroendocrine tumours, roughly triples progression-free survival in the trials, though its final NETTER-1 survival gain was not statistically significant. Pluvicto, for PSMA-positive prostate cancer, extended survival in VISION and has since moved earlier in treatment through PSMAfore and PSMAddition. Both carry bone-marrow, kidney and radiation risks that are managed in hospital. Two questions remain open: whether giving these drugs earlier changes how long people live, which PSMAfore's crossover and NETTER-2's design cannot yet answer, and whether measuring each patient's absorbed dose, rather than giving everyone the same activity, would do better.

Frequently asked questions

How does Lutathera work?

It joins a somatostatin-like peptide to radioactive lutetium-177, so the radiation is carried to neuroendocrine tumour cells that carry somatostatin receptors.

How does Pluvicto work?

It joins PSMA-617, a small molecule that binds prostate-specific membrane antigen, to lutetium-177, delivering radiation to prostate cancer cells.

Does Pluvicto extend survival?

In the VISION trial, median overall survival was 15.3 months with Pluvicto plus standard care against 11.3 months with standard care alone.

What is theranostics?

Using the same targeting molecule twice: first with an imaging isotope to see whether tumours carry the target, then with a therapeutic isotope to treat them.

What is the Lutathera dose?

The US label gives 7.4 GBq (200 mCi) every eight weeks for four doses, for adults and children 12 and older with somatostatin receptor-positive GEP-NETs.

How long does a course of Lutathera or Pluvicto take?

About seven months for Lutathera (four doses eight weeks apart) and up to about nine months for Pluvicto (six doses six weeks apart).

Who can have Pluvicto?

Adults with PSMA-positive metastatic prostate cancer, confirmed by a PSMA PET scan, in the settings on the August 2026 US label: with hormone-pathway therapy for hormone-sensitive disease, or alone for hormone-resistant disease.

What are the main side effects?

Low blood counts, kidney effects, nausea and fatigue; dry mouth is common with Pluvicto. Myelodysplastic syndrome occurred in 2% of treated patients in NETTER-1's follow-up.

Related on Grey Peptides

• Lutetium-177 DOTATATE (Lutathera)
• Vipivotide tetraxetan (Pluvicto)
• Gallium Ga 68 dotatate
• Gozetotide
• Peptide Drug Registry

Sources

1. Advanced Accelerator Applications (Novartis). LUTATHERA (lutetium Lu 177 dotatate) injection, US prescribing information, sections 1 and 2 (DailyMed, effective January 15, 2026); read October 4, 2026.
2. Novartis. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) injection, US prescribing information, sections 1, 2 and 5 (DailyMed, effective August 12, 2026); read October 4, 2026.
3. Advanced Accelerator Applications (Novartis). NETSPOT (kit for gallium Ga 68 dotatate) US prescribing information, section 1 (DailyMed, effective July 6, 2026); read October 4, 2026.
4. Grey Peptides Peptide Drug Registry (assets/registry.json, 770 rows, maximum phase from ChEMBL and FDA records); radioligand and radiotracer rows read October 4, 2026.
5. Strosberg, J., et al. (2017). Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med, 376(2), 125-135. PMID: 28076709
6. Strosberg, J. R., et al. (2021). (177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol, 22(12), 1752-1763. PMID: 34793718
7. Singh, S., et al. (2024). [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet, 403(10446), 2807-2817. PMID: 38851203
8. Sartor, O., et al. (2021). Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med, 385(12), 1091-1103. PMID: 34161051
9. Morris, M. J., et al. (2024). (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet, 404(10459), 1227-1239. PMID: 39293462
10. Tagawa, S. T., et al. (2026). [(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet, 408(10557), 793-807. PMID: 42561994
11. Pavel, M., et al. (2025). Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [(177)Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial. Cancer Med, 14(9), e70744. PMID: 40272146
12. Bodei, L., et al. (2025). Dosimetry of [(177)Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial. J Nucl Med, 66(3), 449-456. PMID: 39947918
13. Murthy, V., et al. (2024). Efficacy and Toxicity of [(177)Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. J Nucl Med, 65(11), 1740-1744. PMID: 39327018
14. Olivier, T., et al. (2023). Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol, 84(1), 4-6. PMID: 36096857
15. Gierulska, N., et al. (2026). PSMA-targeted radioligand therapy in advanced prostate cancer: a narrative review of ^177Lu-PSMA, emerging ^225Ac-PSMA strategies, and therapeutic sequencing. Oncol Rev, 20, 1834484. PMID: 42529062

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.